 |
FAQ | Contact Us | Blog | Partners | News & Events |
Due to their association with a variety of disease states, histone modifying enzymes are attractive therapeutic targets. Although histone modifying enzymes can be difficult to analyze by traditional methods, label-free RapidFire technology is well suited to this novel and emerging class of targets.
Assays for methylases, acetylases, phosphorylases and other modifying enzymes involved in histone and chromatin modulation are developed and optimized by BIOCIUS scientists for primary and secondary screens.
Home Page / Contract Research / Lead Discovery / Custom Assay Dev ...
Custom Assay Development
Streamline drug discovery research
After a target is selected, BIOCIUS scientists develop and optimize proprietary RapidFire screening methods. Our team has taken numerous targets from assay development through lead discovery and has screened tens of millions of test compounds from chemical libraries for clients in the pharmaceutical and biotechnology industries.
By facilitating the screening of intractable targets, RapidFire Custom Assay Development eliminates guesswork from HTS campaigns and provides a reliable foundation on which the drug development process can proceed.
Applications:
- Enzymatic and Kinetic Parameter Determination – Establish Km and linear kinetic ranges
- Determine Z’ scores explore reagent and assay stability, and rank order test compounds
- Hit-to-lead characterization – Determine Ki values and mechanisms of inhibition
Once assay methods are established, they can be used in primary or secondary screening campaigns.
BIOCIUS. Faster Answers.
RapidFire® technology is described in patent numbers 6,932,939, 6,812,030 7,100,460, 7,588,725,